Duoning maintains supply chain stability with operation of factory in Wuxi

SHANGHAI, Dec. 29, 2022 /PRNewswire/ — Wuxi Duoning Factory, one of the seven manufacturing sites owned by Duoning Biotechnology, has been put into operation recently. The factory, through producing culture media and filters, is designed to provide optimal and quality-controlled bioprocess solutions as well as to meet the mass production demands from biopharmaceuticals industry.

Located in the Wuxi-Singapore Industrial Park in Jiangsu Province, the factory covers an area of about 20,000 square meters. Nearly 6000 of those square meters are developed for production lines in accordance with GMP and ISO dual quality system standards. The factory is planned to have three major sections, including three production lines for dry powder cell media (up to 3,000 kilograms), one 4,000 liters liquid cell culture media production line , and production lines for filters. The factory benchmarks itself against the world-class production procedure.

Cell culture media is one of the most important raw materials in the upstream of biopharmaceuticals, while filters are widely used in the bioprocess from upstream to downstream. As of November 31, 2022, Duoning Biotechnology’s cell culture media were used in the highest number of antibody and CGT projects that entered into the BLA stage and commercialization stage among all Chinese cell culture media providers.

Since its establishment in 2005, Duoning Biotechnology has been committed to provide excellent products and services to customers. It also works to learn about customers’ needs and provide cost-effective bioprocess solutions. It will continue to shoulder the mission to build an industry-leading service system to facilitate the long-term growth of the biopharmaceuticals.

About Duoning Biotechnology

Founded in 2005, Shanghai Duoning Biotechnology Co., Ltd. is dedicated to providing one-stop solutions for biopharmaceutical customers, including products and services for biologics products research, development and commercialization.                                                          

*GMP: Good Manufacturing Practice, CGT: Cell and Gene Therapy, BLA: Biologics License Application

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.